| Gene name: | WNT16B |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | MRC-5 |
| Experiment: | SA-β-gal activity assay//BrdU assay |
| Description: | When overexpressed in young MRC5 fibroblasts, WNT16B resulted in an increased percentage of cells positive for SA-β-Gal, a decrease in cell proliferation, and a decrease in bromodeoxyuridine incorporation. |
| Target gene: | P21//P16 |
| Official symbol(s): | P21//P16 |
| R-AG-Target gene: | --//Upregulation |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot |
| Target gene description: | Downregulation of WNT16B also prevented the accumulation of p21WAF1protein；WNT16B overexpression induced moderate p16INK4AmRNA and protein expression. |
| Regulatory pathway: | PI3K-AKT |
| R-AG-Pathway: | Activation |
| Official symbol(s): | PIK3CA-AKT1 |
| Pathway experiment: | Western blot |
| Pathway description: | AKT is also activated in WNT16Bexpressing MRC5 fibroblasts. Moreover, AKT activation was dependent on phosphoinositide 3-kinase (PI3K) activity and was abrogated through treatment with the specific PI3K inhibitor LY294002 . |
Annotation:
Loading,please wait...